EC Approval Adds Small Bullet to Novartis's Growth Arsenal, but Entresto LOE Looms Large

What happened

Novartis secured EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, covering newborns to adults. While this expands the neuroscience pipeline and adds a potential future revenue stream, the near-term financial impact is likely modest given the small patient population and high cost of therapy. The approval does little to offset the accelerating generic erosion of Entresto, which remains a critical headwind to Novartis's top-line growth. The company's premium valuation already prices in strong execution across multiple pipeline assets, leaving little room for disappointment from its concentrated growth drivers. Therefore, while the Itvisma approval is clinically positive, it is inadequate to shift the risk-reward calculus at current levels.

Implication

While Itvisma's broad label is a welcome addition to the neurology pipeline, its commercial contribution will be small relative to the $50B+ revenue base, especially given the presence of established SMA therapies like Biogen's Spinraza and Roche's Evrysdi. The approval does not address the primary thesis risk: whether Kisqali, Kesimpta, Pluvicto, and Scemblix can collectively offset Entresto and Cosentyx erosion and support the 5-6% CAGR. Investors should view this as a typical pipeline milestone that does not justify the current premium multiple of 19.5x earnings. Continue to monitor for upcoming 2026 guidance and Entresto sales trends; if the priority brands disappoint, downward re-rating is likely. Maintain a cautious stance and trim into strength around $155 per the master report's trim threshold.

Thesis delta

This approval does not change our view that Novartis's valuation already reflects optimistic assumptions for its pipeline. Itvisma is a niche product in a competitive space, not a blockbuster that can move the needle. The core thesis remains: at 19.5x trailing P/E, the stock prices in flawless execution of LOE offsets, which is far from guaranteed.